BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26951185)

  • 1. Local excision of low rectal cancer treated by chemoradiotherapy: is it safe for all patients with suspicion of complete tumor response?
    Debove C; Guedj N; Tribillon E; Maggiori L; Zappa M; Panis Y
    Int J Colorectal Dis; 2016 Apr; 31(4):853-60. PubMed ID: 26951185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local excision after neoadjuvant chemoradiotherapy for mid and low rectal cancer: a multicentric French study from the GRECCAR group.
    Calmels M; Labiad C; Lelong B; Lefevre JH; Tuech JJ; Benoist S; Mège D; Denost Q; Panis Y
    Colorectal Dis; 2023 Oct; 25(10):1973-1980. PubMed ID: 37679892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
    Jung SM; Yu CS; Park IJ; Kim TW; Kim JH; Yoon YS; Lim SB; Kim JC
    Medicine (Baltimore); 2016 May; 95(20):e3718. PubMed ID: 27196490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local excision for ypT2 rectal cancer following preoperative chemoradiation therapy: it should not be justified.
    Yang KM; Lim SB; Lee JL; Kim CW; Yoon YS; Park IJ; Yu CS; Kim JC
    Int J Colorectal Dis; 2018 Apr; 33(4):487-491. PubMed ID: 29468352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it time to rethink the rule of total mesorectal excision? A prospective radiological and pathological study in 49 consecutive patients with mid-rectal cancer.
    Guedj N; Zappa M; Maggiori L; Bertin C; Hennequin C; Panis Y
    Colorectal Dis; 2016 Sep; 18(9):O314-21. PubMed ID: 27381492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local excision after neoadjuvant chemoradiotherapy versus total mesorectal excision: a case-matched study in 110 selected high-risk patients with rectal cancer.
    Calmels M; Collard MK; Cazelles A; Frontali A; Maggiori L; Panis Y
    Colorectal Dis; 2020 Dec; 22(12):1999-2007. PubMed ID: 32813899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.
    Belluco C; Forlin M; Olivieri M; Cannizzaro R; Canzonieri V; Buonadonna A; Bidoli E; Matrone F; Bertola G; De Paoli A
    Ann Surg Oncol; 2016 Dec; 23(13):4302-4309. PubMed ID: 27489059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total Mesorectal Excision Versus Local Excision After Favorable Response to Preoperative Chemoradiotherapy in "Early" Clinical T3 Rectal Cancer: A Propensity Score Analysis.
    Shin YS; Yu CS; Park JH; Kim JC; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Yoon SM; Joo JH; Kim JH
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):136-144. PubMed ID: 28816139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].
    Sprenger T; Rothe H; Beissbarth T; Conradi LC; Kauffels A; Homayounfar K; Behnes CL; Rödel C; Liersch T; Ghadimi M
    Chirurg; 2016 Jul; 87(7):593-601. PubMed ID: 27106241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Mesorectal Excision Versus Local Excision After Preoperative Chemoradiotherapy in Rectal Cancer With Lymph Node Metastasis: A Propensity Score-Matched Analysis.
    Shin YS; Park JH; Yoon SM; Kim JC; Yu CS; Lim SB; Park IJ; Kim TW; Hong YS; Kim KP; Choi EK; Ahn SD; Lee SW; Kim JH
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):630-639. PubMed ID: 29678529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial.
    Lee JL; Lim SB; Yu CS; Park IJ; Yoon YS; Kim CW; Park SH; Lee JS; Hong YS; Kim SY; Kim JE; Kim JH; Park JH; Kim J; Han M
    BMC Cancer; 2019 Apr; 19(1):404. PubMed ID: 31035949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-inferiority multicenter prospective randomized controlled study of rectal cancer T
    Serra-Aracil X; Pericay C; Golda T; Mora L; Targarona E; Delgado S; Reina A; Vallribera F; Enriquez-Navascues JM; Serra-Pla S; Garcia-Pacheco JC;
    Int J Colorectal Dis; 2018 Feb; 33(2):241-249. PubMed ID: 29234923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer.
    Borschitz T; Wachtlin D; Möhler M; Schmidberger H; Junginger T
    Ann Surg Oncol; 2008 Mar; 15(3):712-20. PubMed ID: 18163173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualizing surgical treatment based on tumour response following neoadjuvant therapy in T4 primary rectal cancer.
    Denost Q; Kontovounisios C; Rasheed S; Chevalier R; Brasio R; Capdepont M; Rullier E; Tekkis PP
    Eur J Surg Oncol; 2017 Jan; 43(1):92-99. PubMed ID: 27717529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy.
    Bosch SL; Vermeer TA; West NP; Swellengrebel HA; Marijnen CA; Cats A; Verhoef C; van Lijnschoten I; de Wilt JH; Rutten HJ; Nagtegaal ID
    Histopathology; 2016 Nov; 69(5):839-848. PubMed ID: 27270756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.
    von den Grün JM; Hartmann A; Fietkau R; Ghadimi M; Liersch T; Hohenberger W; Weitz J; Sauer R; Wittekind C; Ströbel P; Rödel C; Fokas E;
    Radiother Oncol; 2018 Sep; 128(3):557-563. PubMed ID: 29929861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic outcome after preoperative chemoradiotherapy in patients with pathologic T0 (ypT0) rectal cancer.
    Jang TY; Yu CS; Yoon YS; Lim SB; Hong SM; Kim TW; Kim JH; Kim JC
    Dis Colon Rectum; 2012 Oct; 55(10):1024-31. PubMed ID: 22965400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term outcomes in ypT2 rectal cancer patients after neoadjuvant therapy and local excision: a multicentre observational study.
    Peltrini R; Castiglioni S; Imperatore N; Ortenzi M; Rega D; Romeo V; Caracino V; Liberatore E; Basti M; Santoro E; Bracale U; Delrio P; Mucilli F; Guerrieri M; Corcione F
    Tech Coloproctol; 2023 Jan; 27(1):53-61. PubMed ID: 36239872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
    Akiyoshi T; Ueno M; Matsueda K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Unno T; Kano A; Kuroyanagi H; Oya M; Yamaguchi T; Watanabe T; Muto T
    Ann Surg Oncol; 2014 Jan; 21(1):189-96. PubMed ID: 23963871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.